Synutra Reports First Quarter Fiscal 2012 Financial Results

Branded Formula Sales Demonstrate Sustained Recovery

1Q12 Formula Sales were $40.2 million

1Q12 Gross Margin Rose to 36.7%

Aug 09, 2011, 16:01 ET from Synutra International, Inc.

QINGDAO, China and ROCKVILLE, Md., Aug. 9, 2011 /PRNewswire-Asia/ -- Synutra International, Inc. (NASDAQ: SYUT), a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today announced financial results for the first quarter of fiscal 2012 ended June 30, 2011.

Mr. Liang Zhang, Chairman and CEO of Synutra, remarked, "We are pleased with the continued recovery of our branded formula sales.  Though there is significant room for improvement before we reach our targeted performance goals, we believe our branded formula sales demonstrate that our recovery is ongoing and sustainable.  Quality, especially for domestic infant dairy producers, continues to grow in prominence in the eyes of China's consumers.  As such, we believe we are well-positioned with our focus on premium quality brands to gain greater consumer recognition."

Mr. Donghao Yang, Chief Financial Officer of Synutra, commented, "We do recognize our first quarter 2012 topline performance shows significant volatility versus prior quarters.  This is due to two main factors.  The majority of the difference is attributable to our decision not to enter into industrial milk powder sales this quarter.  In the past, we have used these sales as a form of short-term financing.  We are pleased to note that as our sales performance strengthened, we we were able to meet our short-term cash requirements. In addition, it is also important to note that $16.6 million of formula sales were shifted from the June quarter to early July.  A series of events led to this revenue shift but it primarily reflects whey powder delivery timing from our French supplier.  Our management team acted quickly to identify an alternate source and we were able to make up much of the delayed sales by early July through working overtime.  More importantly, this issue has been resolved.  We have secured a reliable interim supplier and our French supplier will begin regular shipments in August."

"As an infant formula company, Synutra's performance is best tracked through its powdered formula sales.  Accounting for the shipment delay, our formula sales in the June quarter would have increased by $8.4 million from the March quarter.  Furthermore, as you can see from the increase in raw materials and inventory on our balance sheet, we are quickly ramping up to meet the incoming order demand.  We are proud of this achievement and believe that this marks only the first of many quarters of sustained sales growth and margin enhancement," Mr. Yang concluded.

Financial Results for the First Quarter of Fiscal 2012 versus the Fourth Quarter of Fiscal 2011

Quarter Ended

QoQ Change

June 30, 2011

March 31, 2011

(in USD 000's except per share and percentage data)

Net sales

43,757

79,294

(35,537)

(44.8%)

Cost of sales

27,678

61,826

(34,148)

(55.2%)

Gross profit

16,079

17,468

(1,389)

(8.0%)

Gross margin

36.7%

22.0%

Selling and distribution expenses

12,461

10,858

1,603

14.8%

Advertising and promotion expenses

7,008

6,313

695

11.0%

General and administrative expenses

6,579

7,685

(1,106)

(14.4%)

Other operating income, net

110

957

(847)

(88.5%)

Total operating expense

25,938

23,899

2,039

8.5%

Loss from operations

(9,859)

(6,431)

(3,428)

53.3%

Operating margin

(22.5%)

(8.1%)

Net interest expense and other income

2,636

2,553

83

3.3%

Income tax benefit

3,049

384

2,665

694.0%

Net income (loss) attributable to the noncontrolling interest

150

(61)

211

(345.9%)

Net loss attributable to Synutra International, Inc. common stockholders

(9,596)

(8,539)

(1,057)

12.4%

Net margin

(21.9%)

(10.8%)

Loss per share – Diluted

($0.17)

($0.15)

($0.02)

12.4%

Net sales were $43.8 million for the first quarter of fiscal 2012 compared to $79.3 million in the fourth quarter of fiscal 2011, reflecting lower industrial milk powder sales and delay of revenue recognition into early July due to timing of whey protein powder shipments during the quarter. Net sales from the Company's branded powdered formula segment were $40.2 million, or 91.8% of net sales in the quarter, compared to $48.3 million, or 60.9% of net sales, in the previous quarter. Net sales of the Company's Super series infant formula accounted for 58.4% of the volume of sales and 70.4% of the net sales of the powdered formula segment for the first quarter of fiscal year 2012 compared to 53.9% of the volume of sales and 65.8% of the net sales of the powdered formula segment in the previous quarter. By volume, sales of powdered formula products were 4,513 tons in the fiscal first quarter compared to 6,057 tons in the previous quarter.  

Net sales from Other Products, which generally consists of surplus milk powder, whey protein and raw milk sold to industrial customers, was $3.1 million, or 7.0% of net sales, in the first quarter of fiscal 2012, compared to $30.8 million, or 38.8% of net sales in the previous quarter. The decrease reflects the Company's decision to not enter into sales of industrial milk powder in the first quarter of fiscal 2012 to enhance profitability as opposed to the prior quarter, where industrial milk powder sales were used as short-term financing to meet working capital needs.

Gross profit was $16.1 million in the first quarter of fiscal 2012, compared to $17.5 million in the previous quarter. Gross margin in the first quarter of fiscal 2012 was 36.7%, compared to 22.0% in the previous quarter. This continues to reflect the impact of the discounts the Company provided to distributors to regain market share but the sequential improvement reflects a product mix shift towards a greater proportion of higher margin, branded formula sales as well as the effectiveness of the Company's efforts to strengthen distribution channels.

Loss from operations was $9.9 million compared to a loss from operations of $6.4 million in the previous quarter. Total operating expense remained predominantly steady from the previous quarter but reflects higher bonus expenses for the sales team. Selling and distribution expenses increased 14.8% to $12.5 million from $10.9 million. Advertising and promotional expenses were $7.0 million, compared to $6.3 million in the previous quarter. General and administrative expenses were $6.6 million compared to $7.7 million in the previous quarter.

Net loss attributable to Synutra International, Inc. common stockholders was $9.6 million in first quarter fiscal year 2012, or ($0.17) per diluted share, compared with a net loss of $8.5 million, or ($0.15) per diluted share in the previous quarter.

Mr. Yang continued, "One of the key highlights this quarter was the upward trend of our market share. This further supports our belief that our recovery is a sustained and ongoing trend.  Our May and June quarters were affected by product shipment delays but our overall direction and market share position demonstrates that consumer demand for our products is recovering."

April

May

June

July

(In thousands except percentage)

Net sales of powdered formula segment

14,504

12,244

13,415

34,676*

Market Share (CIC data)

4.3%

4.6%

5.3%

N/A

* Includes $16.6 million of revenue delayed from June to early July

Balance Sheet

As of June 30, 2011, the Company had cash and cash equivalents of $27.5 million and restricted cash of $52.8 million.

Mr. Zhang stated in closing, "We believe Synutra has embarked upon a path of sustainable recovery.  This will be a gradual process with many challenges along the way.  However, we continue to be confident in the long-term potential of both Synutra and China's domestic infant formula market and believe our dedication to high quality products and a robust nationwide distribution network will drive our long-term growth momentum."

Conference Call Details

The Company will hold a conference call on Wednesday, August 10, 2011 at 8:00 am Eastern Time to discuss the financial results.  Listeners may access the call by dialing the following numbers:

United States Toll Free:                        

+1 (866) 405-2350

International:

+1 (718) 354-1231

Conference ID:

83225375

The replay will be accessible through August 18, 2011 by dialing the following numbers:

United States Toll Free:                        

+1 (866) 214-5335

International:

+1 (718) 354-1232

Conference ID:

83225375

A webcast of the conference call will be available through the Company's IR website at www.synutra.com.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering 30 provinces and provincial-level municipalities in China. As of June 30, 2011, this network comprised over 630 independent distributors and over 1,000 independent sub-distributors who sell Synutra products in over 69,000 retail outlets.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra International, Inc. and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "is/are likely to," "may," "plan," "should," "will," "aim," "potential," "continue," or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra's goals and strategies; its future business development, financial condition and results of operations; the expected growth of the nutritional products and infant formula markets in China; market acceptance of Synutra's products; the safety and quality of Synutra's products; Synutra's expectations regarding demand for its products; Synutra's ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra's actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in Synutra's filings with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this press release. Synutra International, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

FOR FURTHER INFORMATION:

Synutra International, Inc.                                                

Investor Relations Department

ir@synutra.com or +1-301-840-3881

Synutra International, Inc.

Consolidated Statements of Income

Three Months Ended June 30,

2011

2010

(in thousands except earnings per share data)

Net sales

$

43,757

$

83,787

Cost of sales

27,678

37,426

Gross profit

16,079

46,361

Selling and distribution expenses

12,461

12,626

Advertising and promotion expenses

7,008

10,002

General and administrative expenses

6,579

6,076

Impairment of goodwill

-

1,440

Other operating income, net

110

73

Income (loss) from operations

(9,859)

16,290

Interest expense

3,412

2,662

Interest income

311

108

Other income, net

465

167

Income (loss) before income tax expense (benefit)

(12,495)

13,903

Income tax expense (benefit)

(3,049)

3,795

Net income (loss)

(9,446)

10,108

Net income attributable to the noncontrolling interest

150

2

Net income (loss) attributable to Synutra International, Inc. common stockholders

$

(9,596)

$

10,106

Earnings (loss) per share - basic

$

(0.17)

$

0.19

Earnings (loss) per share - diluted

$

(0.17)

$

0.19

Weighted average common share outstanding - basic

57,301

54,037

Weighted average common share outstanding - diluted

57,301

54,274

Synutra International, Inc.

Consolidated Balance Sheets

June 30, 2011

March 31, 2011

(in thousands, except share par value)

ASSETS

Current Assets:

Cash and cash equivalents

$

27,537

$

48,741

Restricted cash

52,778

37,690

Accounts receivable, net of allowance

27,609

46,021

Inventories

94,780

67,372

Due from related parties

3,666

13,708

Income tax receivable

3,347

259

Receivable from assets disposal

1,736

1,714

Prepaid expenses and other current assets

20,900

11,562

Deferred tax assets

21,216

20,922

Total current assets

253,569

247,989

Property, plant and equipment, net

113,528

109,811

Land use rights, net

6,138

6,096

Intangible assets, net

3,149

3,140

Other assets

3,656

4,022

Deferred tax assets

27,976

27,646

TOTAL ASSETS

$

408,016

$

398,704

LIABILITIES AND EQUITY

Current Liabilities:

Short-term debt

$

111,424

$

124,281

Long-term debt due within one year

67,989

38,131

Accounts payable

61,028

52,923

Due to related parties

2,166

2,330

Advances from customers

11,580

4,890

Other current liabilities

23,320

25,913

Total current liabilities

277,507

248,468

Long-term debt

51,182

62,722

Deferred revenue

4,450

4,456

Capital lease obligations

5,605

5,540

Other long-term liabilities

1,619

1,592

Total liabilities

340,363

322,778

Equity:

Synutra International, Inc. shareholders' equity

Common stock, $.0001 par value: 250,000 authorized; 57,301 and 57,301 issued and outstanding at June 30, 2011 and March 31, 2011, respectively

6

6

Additional paid-in capital

135,440

135,440

Accumulated deficit

(97,953)

(88,357)

Accumulated other comprehensive income

29,353

28,204

Total Synutra common stockholders’ equity

66,846

75,293

Noncontrolling interest

807

633

Total equity

67,653

75,926

TOTAL LIABILITIES AND EQUITY

$

408,016

$

398,704

SOURCE Synutra International, Inc.



RELATED LINKS

www.synutra.com